Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination drug consisting of **allopurinol** (a xanthine oxidase inhibitor primarily used to lower uric acid levels), **ascorbic acid** (Vitamin C, an antioxidant and reducing agent), and **cyclodextrin** (a cyclic oligosaccharide often used to enhance the solubility and stability of pharmaceutical compounds). - **Mechanism of Action**: - Allopurinol inhibits **xanthine oxidase**, lowering serum and urine uric acid concentrations and reducing risk of gout and kidney stones[1][7]. - Ascorbic acid participates in redox reactions and may enhance antioxidant capacity in blood, potentially influencing cardiovascular or metabolic endpoints[2]. - Cyclodextrin acts as a carrier and solubilizer for the other drugs, shown experimentally to improve the dissolution and pharmacokinetic properties of allopurinol and facilitate the quantification/interaction with uric acid and ascorbic acid[2][6]. - **Primary Indication**: Although not a marketed product, this combination may be used for enhanced management of hyperuricemia or gout, possibly improving solubility, bioavailability, and assay sensitivity for uric acid and ascorbic acid in serum[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allopurinol + ascorbic acid + cyclodextrin.